Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CBIO advanced for three days, in 197 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CBIO's RSI Indicator exited the oversold zone, 31 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 62 cases where CBIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for CBIO just turned positive on October 21, 2026. Looking at past instances where CBIO's MACD turned positive, the stock continued to rise in 31 of 40 cases over the following month. The odds of a continued upward trend are 77%.
CBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CBIO as a result. In 88 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
CBIO moved below its 50-day moving average on September 17, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CBIO crossed bearishly below the 50-day moving average on September 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CBIO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.065) is normal, around the industry mean (2.973). CBIO has a moderately low P/E Ratio (-93.857) as compared to the industry average of (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (35.461) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. CBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
SMMT saw its Momentum Indicator move below the 0 level on October 13, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 103 similar instances where the indicator turned negative. In 89 of the 103 cases, the stock moved further down in the following days. The odds of a decline are at 86%.
The Moving Average Convergence Divergence Histogram (MACD) for SMMT turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 38 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
SMMT moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SMMT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 61 of 69 cases where SMMT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
Following a +9.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where SMMT advanced for three days, in 244 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
SMMT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 123 of 148 cases where SMMT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. SMMT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SMMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.691) is normal, around the industry mean (2.973). P/E Ratio (-14.009) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.310) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
CBIO | SMMT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 64 | 93 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 2 Undervalued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 57 | 71 | |
SMR RATING 1..100 | 99 | 100 | |
PRICE GROWTH RATING 1..100 | 65 | 61 | |
P/E GROWTH RATING 1..100 | 26 | 59 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CBIO's Valuation (2) in the Biotechnology industry is significantly better than the same rating for SMMT (90). This means that CBIO’s stock grew significantly faster than SMMT’s over the last 12 months.
CBIO's Profit vs Risk Rating (57) in the Biotechnology industry is in the same range as SMMT (71). This means that CBIO’s stock grew similarly to SMMT’s over the last 12 months.
CBIO's SMR Rating (99) in the Biotechnology industry is in the same range as SMMT (100). This means that CBIO’s stock grew similarly to SMMT’s over the last 12 months.
SMMT's Price Growth Rating (61) in the Biotechnology industry is in the same range as CBIO (65). This means that SMMT’s stock grew similarly to CBIO’s over the last 12 months.
CBIO's P/E Growth Rating (26) in the Biotechnology industry is somewhat better than the same rating for SMMT (59). This means that CBIO’s stock grew somewhat faster than SMMT’s over the last 12 months.
| CBIO | SMMT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 84% | N/A |
| Stochastic ODDS (%) | 1 day ago 82% | 1 day ago 88% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| MACD ODDS (%) | 1 day ago 77% | 1 day ago 79% |
| TrendWeek ODDS (%) | 1 day ago 85% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 86% |
| Advances ODDS (%) | 2 days ago 84% | 3 days ago 86% |
| Declines ODDS (%) | 7 days ago 88% | 1 day ago 84% |
| BollingerBands ODDS (%) | 1 day ago 83% | 1 day ago 86% |
| Aroon ODDS (%) | 1 day ago 88% | 1 day ago 83% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CBIO’s FA Score shows that 2 FA rating(s) are green while SMMT’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CBIO’s TA Score shows that 5 TA indicator(s) are bullish while SMMT’s TA Score has 4 bullish TA indicator(s).
CBIO (@Biotechnology) experienced а +5.29% price change this week, while SMMT (@Biotechnology) price change was +1.17% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
CBIO is expected to report earnings on Nov 05, 2026.
SMMT is expected to report earnings on Oct 26, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, CBIO has been loosely correlated with EDIT. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CBIO jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To CBIO | 1D Price Change % | ||
|---|---|---|---|---|
| CBIO | 100% | -0.23% | ||
| EDIT - CBIO | 37% Loosely correlated | -0.80% | ||
| SMMT - CBIO | 37% Loosely correlated | -1.77% | ||
| UTHR - CBIO | 36% Loosely correlated | +3.78% | ||
| STRO - CBIO | 34% Loosely correlated | -4.63% | ||
| PRTA - CBIO | 34% Loosely correlated | +2.74% | ||
More | ||||
A.I.dvisor indicates that over the last year, SMMT has been closely correlated with BCDA. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if SMMT jumps, then BCDA could also see price increases.
| Ticker / NAME | Correlation To SMMT | 1D Price Change % | ||
|---|---|---|---|---|
| SMMT | 100% | -1.77% | ||
| BCDA - SMMT | 70% Closely correlated | -5.47% | ||
| SNDX - SMMT | 42% Loosely correlated | +3.19% | ||
| KURA - SMMT | 42% Loosely correlated | -0.20% | ||
| LXEO - SMMT | 41% Loosely correlated | -3.67% | ||
| CBIO - SMMT | 41% Loosely correlated | -0.23% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| BTC.X | 81311.890000 | -2700.078100 | -3.21% |
| Bitcoin cryptocurrency | |||
| THETA.X | 0.194462 | -0.007331 | -3.63% |
| Theta Network cryptocurrency | |||
| DYM.X | 0.018908 | -0.000858 | -4.34% |
| Dymension cryptocurrency | |||
| IOTX.X | 0.004007 | -0.000218 | -5.16% |
| IoTeX cryptocurrency | |||
| YFII.X | 22.921904 | -2.300772 | -9.12% |
| DFI.Money cryptocurrency | |||